Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab

Launched by CHRISTOPH KÖNIGS · Apr 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain antibodies behave in patients with severe hemophilia A who are being treated with a medication called emicizumab. Hemophilia A is a bleeding disorder where the blood does not clot properly. Emicizumab helps patients manage their condition by allowing their blood to clot more effectively. The researchers want to understand how these antibodies change over time during treatment. This study does not require any extra visits or procedures; instead, it will use leftover samples from routine check-ups that patients already have.

To participate in this study, individuals must have severe hemophilia A and be currently receiving emicizumab treatment. They should not be receiving other specific treatments that could interfere with the study, such as immunosuppressive therapy. Participants can continue with their regular care while contributing to this important research, which aims to improve understanding and treatment of hemophilia A.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Severe congenital hemophilia A (CHA)
• • Treatment with emicizumab irrespective of any other treatment
• • Informed consent
• Exclusion Criteria:
• • No therapy with emicizumab
• • Immunosuppressive therapy
• • HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl